Elizabeth C. S. Swart

Elizabeth C. S. Swart

Auto-generated profile, based on publicly available information

Elizabeth C. S. Swart

Value-Based Pharmacy Initiatives, UPMC Center for High-Value Health Care, Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
TNTerri V. Newman
Terri V. Newman
ASAlvaro San-Juan-Rodriguez
Alvaro San-Juan-Rodriguez
NPNatasha Parekh
Natasha Parekh
ESElizabeth C.S. Swart
Elizabeth C.S. Swart
MKMichele Klein-Fedyshin
Michele Klein-Fedyshin
IHInmaculada Hernandez
Inmaculada Hernandez

1 October 2018 in Preventive Medicine
Verified
Journal Article
Closed access
ASAlvaro San-Juan-Rodriguez
Alvaro San-Juan-Rodriguez
TNTerri V. Newman
Terri V. Newman
IHInmaculada Hernandez
Inmaculada Hernandez
ESElizabeth C.S. Swart
Elizabeth C.S. Swart
MKMichele Klein-Fedyshin
Michele Klein-Fedyshin
NPNatasha Parekh
Natasha Parekh

1 September 2019 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Closed access
TNTerri V. Newman
Terri V. Newman
IHInmaculada Hernandez
Inmaculada Hernandez
DKDonna Keyser
Donna Keyser
ARAlvaro San-Juan Rodriguez
Alvaro San-Juan Rodriguez
ESElizabeth C.S. Swart
Elizabeth C.S. Swart
NPNatasha Parekh
Natasha Parekh
The shift to a value-based health care system has incentivized providers to implement strategies that improve population health outcomes while minimizing downstream costs. Given their accessibility...

6 January 2020 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
CVClark A. Veet
Clark A. Veet
TRThomas R. Radomski
Thomas R. Radomski
CDChristopher D’aVella
Christopher D’aVella
IHInmaculada Hernandez
Inmaculada Hernandez
CWCharles Wessel
Charles Wessel
NPNatasha Parekh
Natasha Parekh

29 June 2021 in Medical Care
Verified
Journal Article
Closed access
LNLynn M. Neilson
Lynn M. Neilson
KMKiraat D. Munshi
Kiraat D. Munshi
SPSamuel K. PhD Peasah
Samuel K. PhD Peasah
YHYan Huang
Yan Huang
ESElizabeth C.S. Bs Swart
Elizabeth C.S. Bs Swart
CGChester B. Good
Chester B. Good
Objective: The objective of this study was to describe national changes in utilization and associated costs of antidiabetic medications in the United States from 2014 to 2019, across different drug classes and insurance plans. Research Design and Methods: This retrospective, cross-sectional study examined administrative claims from a large national pharmacy benefits manager from January 1, 2014, to December 31, 2019. Patients aged 18 years and above enrolled in commercial, Medicare, or Medicaid health plans who filled ≥1 prescription claim for an antidiabetic medication(s) during the 6-year period were included. Utilization was examined as the total number of 30-day adjusted prescription fills per user per month (PUPM). Gross costs were calculated as the sum of plan costs (net of rebates) and member out-of-pocket costs. Differences in mean utilization and costs PUPM between 2014 and 2019 for each medication class were calculated. Results: The final analytic sample increased from 745,290 patients in 2014 to 1,596,006 in 2019. Antidiabetic medication utilization increased by 8.8% from 2014 to 2019, driven by increases in sodium-glucose cotransporter 2 inhibitor (48.7%; P<0.001), glucagon-like peptide 1 receptor agonist (11.8%; P<0.001), insulin (8.1%; P<0.001), and metformin (2.9%; P<0.05) utilization. Average costs PUPM rose 47.5% (P<0.001), from $126.52 in 2014 to $186.58 in 2019. Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and combination drugs contributed significantly to these increased costs, with 6-year cost differences of 57.3%, 46.9%, and 47.2%, respectively (all P<0.001). Conclusion: Our study demonstrates a shift in antidiabetic medication class utilization from 2014 to 2019, where associated costs net of rebates significantly increased to a disproportionately greater extent than the significant increase in utilization PUPM.

1 May 2022 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
JAJoe Angelelli
Joe Angelelli
DMDavid McCartney
David McCartney
CRChristian Roehmer
Christian Roehmer
ESElizabeth C.S. Swart
Elizabeth C.S. Swart
EQEleanor Quinby
Eleanor Quinby
BDBrad Dicianno
Brad Dicianno